scispace - formally typeset
Search or ask a question

Showing papers by "Silvia C. Formenti published in 1999"


Journal Article
TL;DR: Preliminary results suggest that twice-weekly dosing of paclitaxel may optimize recruitment of cells into the G2/M phase of the cell cycle, the most radiosensitive phase, and suggest that the peak apoptotic index occurs at approximately 72 hours after pac litaxel administration and decreases at approximately 98 hours.

64 citations


Journal Article
TL;DR: P-glycoprotein was not expressed in breast carcinoma cells at significant levels, although it was expressed in stomal lymphocytes or macrophages, and results suggest that P- glycoprotein does not play a significant role in multidrug resistance of breast cancer.

44 citations


Journal ArticleDOI
01 Jun 1999-Urology
TL;DR: It is recommended the use of moderate dose, limited-field postoperative radiotherapy in patients with pathologic Stage C disease with Gleason score greater than 4, on the basis of the experience of this study.

24 citations


Journal ArticleDOI
TL;DR: The use of moderate-dose postoperative radiotherapy was of low toxicity and it did not increase the incidence of incontinence and Adjuvant RT probably reduces the risk of recurrence in patients with poor prognostic factors.
Abstract: Patients with localized adenocarcinoma of the prostate gland (CaP) are frequently (approximately 50%) found at radical prostatectomy to have extracapsular disease or positive surgical margins. The management of these patients is a subject of controversy because some question the impact of this manifestation of CaP on patient survival or disease-free survival. Between 1976 and 1991, 241 patients with pathologic stage C (T3N0) were treated in this medical center. Of these 241 patients, 201 (83%) received a planned postoperative pelvic irradiation consisting of 48 Gy given to the prostatic fossa, whereas 40 (17%) patients were treated with radical prostatectomy alone. The two study urologists selected these patients not to receive postoperative irradiation based on intraoperative findings and important prognostic factors. Comparison of treatment outcomes in these two treatment groups is a subject of this report. The 201 patients treated with surgery-radiotherapy (S+RT) combination had a higher pathologic stage, greater incidence of seminal vesicle involvement, p = 0.002, and higher mean and median preoperative prostate-specific antigen level, p < 0.0001, than the 40 surgery (S) alone patients. There was no significant difference in the incidence of higher Gleason's score by the treatment group, p = 0.14. In univariate analysis, there was no significant difference in survival, disease-free survival, and time to failure between the two treatment groups. In multivariate analysis after controlling for pathologic stage and Gleason's score, the 201 adjuvant radiotherapy patients were predicted to have recurrence at 68% (95% confidence interval 39%-118%) the rate of the 40 surgery-alone patients. Local recurrence with or without metastatic disease was found in 10% of surgery-alone patients as compared to 5% in those also receiving postoperative irradiation. Treatment tolerance was very good with minor radiotherapy complications only. There was no significant difference in the incidence of incontinence between the two treatment arms. In summary: (a) The use of moderate-dose postoperative radiotherapy was of low toxicity and it did not increase the incidence of incontinence. (b) Local recurrence was 5% in S+RT and 10% in S-alone patients. (c) In multivariate analysis, S+RT patients had 68% rate of recurrence of S-alone patients. (d) Adjuvant RT probably reduces the risk of recurrence in patients with poor prognostic factors. (e) These data need to be interpreted with caution because of the nonrandomized nature of the study.

19 citations


Book ChapterDOI
01 Jan 1999
TL;DR: The NSABP-B6 study confirms the high incidence of breast cancer recurrence in patients undergoing wide excision without radiation, with 37% local recurrences in node-negative patients and 43% in nodes-positive patients.
Abstract: It is now generally agreed that conservative surgery with radiation represents a valid alternative to mastectomy for treatment of stage I and II breast cancer. At present, seven prospective randomized trials have shown the equivalence of mastectomy versus conservative surgery and radiotherapy in terms of local recurrence, 5- and 10-year disease-free survival, and overall survival.1,2 Postoperative irradiation represents a fundamental component of conservative management and the NSABP-B6 study confirms the high incidence of breast cancer recurrence in patients undergoing wide excision without radiation, with 37% local recurrences in node-negative patients and 43% in node-positive patients. Instead, locoregional recurrence following conservative surgery and irradiation for early breast cancer ranges from 5% to 10% at 5 years and from 10% to 15% at 10 years.3 These figures are comparable to those achieved with mastectomy.

2 citations


Journal ArticleDOI
TL;DR: Some of the ongoing controversies concerning the use of radiation therapy in the multidisciplinary management of breast cancer are summarized.
Abstract: Radiation therapy plays an important role in the management of both invasive and noninvasive breast cancer. During the last 20 years, the availability of radiation therapy has made it possible to test the feasibility and safety of breast preservation after the diagnosis of early-stage breast cancer. This article summarizes some of the ongoing controversies concerning the use of radiation therapy in the multidisciplinary management of breast cancer.

1 citations